Skip to content
New: 30 more Indian companies explained, from Ather and Pine Labs to IDBI Bank

Sector

Healthcare sector explained

Companies that make medicines, vaccines and medical devices, and those that run hospitals and diagnostic labs.

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Companies we cover

14 companies in Healthcare

  • Apollo Hospitals treats patients in 48 hospitals of its own and supplies 7,662 Apollo pharmacies; FY26 revenue was ₹24,774 crore.

    Filings cover: A lotUpdated for Q2 FY27 · checked

  • Aurobindo Pharma makes generic medicines and drug ingredients, mostly sold in the US and Europe, and earned ₹33,653 crore of revenue in FY26.

    Filings cover: SomeUpdated for Q2 FY27 · checked

  • Cipla

    CIPLA

    Cipla makes medicines, including inhalers for breathing conditions, and sells them in India, the US, Africa and other markets, earning ₹28,163 crore of revenue in FY26.

    Filings cover: A lotUpdated for Q2 FY27 · checked

  • Divi's Laboratories makes medicine ingredients for drug companies, mostly abroad, earning ₹10,560 crore of revenue in FY26.

    Filings cover: SomeUpdated for Q2 FY27 · checked

  • Dr. Reddy's makes generic and branded medicines and their ingredients, and sells them in 87 countries; FY26 revenue was ₹33,700 crore.

    Filings cover: A lotUpdated for Q2 FY27 · checked

  • Lupin

    LUPIN

    Lupin makes generic medicines for the US and branded medicines for India, earning ₹27,958 crore of revenue in FY26.

    Filings cover: A lotUpdated for Q2 FY27 · checked

  • Marksans Pharma makes generic medicines, mostly over-the-counter products such as painkillers, for the US, UK, Europe and Australia, earning ₹2,951 crore of revenue in FY26.

    Filings cover: A lotUpdated for Q2 FY27 · checked

  • Max Healthcare runs private hospitals, mainly in metro cities and especially Delhi NCR, and earned ₹8,373 crore of consolidated revenue in FY26.

    Filings cover: SomeUpdated for Q2 FY27 · checked

  • Morepen Laboratories makes medicine ingredients for drug companies and glucose meters for home use, earning ₹1,806 crore of revenue in FY26.

    Filings cover: SomeUpdated for Q2 FY27 · checked

  • Natco Pharma

    NATCOPHARM

    Natco Pharma develops complex generic medicines that partner companies sell in the US, and sells cancer medicines in India, earning ₹4,078 crore of revenue in FY26.

    Filings cover: SomeUpdated for Q2 FY27 · checked

  • Piramal Pharma makes medicines under contract for other drug companies, sells anaesthesia and other hospital medicines, and owns Indian consumer brands; FY26 revenue was ₹8,869 crore.

    Filings cover: SomeUpdated for Q2 FY27 · checked

  • Sun Pharma

    SUNPHARMA

    Sun Pharma makes medicines sold in more than 100 countries, including India and the US, earning ₹58,462 crore of revenue in FY26.

    Filings cover: A lotUpdated for Q2 FY27 · checked

  • Torrent Pharma

    TORNTPHARM

    Torrent Pharma makes branded medicines for India and Brazil and generic medicines for the US and Germany, earning ₹13,980 crore of revenue in FY26.

    Filings cover: SomeUpdated for Q2 FY27 · checked

  • Zydus Lifesciences makes generic medicines for the US and branded medicines for India, and earned ₹27,148 crore of revenue in FY26.

    Filings cover: A lotUpdated for Q2 FY27 · checked

The companies side by side

Each figure is from the company's own page, for its latest full financial year (April to March) unless a date is shown. Select a column heading to re-order the rows.

Healthcare companies on Cityfort: revenue, net profit per ₹100 of revenue, free cash flow, debt-to-equity and last update
CompanyRevenueNet profit per ₹100 of revenueFree cash flowDebt-to-equityPage last updated
Apollo Hospitals (APOLLOHOSP)₹24,774 crFY26₹7.8FY26₹894 crFY260.53as of 30 Sep 202611 Nov 2026
Aurobindo Pharma (AUROPHARMA)₹33,653 crFY26₹10.4FY26₹2,422 crFY260.2as of 31 Mar 202616 Nov 2026
Cipla (CIPLA)₹28,163 crFY26₹13.8FY26₹861 crFY260.01as of 30 Sep 202611 Nov 2026
Divi's Laboratories (DIVISLAB)₹10,560 crFY26₹24.3FY26₹218 crFY260as of 30 Sep 202612 Nov 2026
Dr. Reddy's (DRREDDY)₹33,700 crFY26₹12.5FY26₹1,833 crFY260.15as of 30 Sep 202617 Nov 2026
Lupin (LUPIN)₹27,958 crFY26₹19.1FY26₹5,280 crFY260.23as of 30 Sep 202616 Nov 2026
Marksans Pharma (MARKSANS)₹2,951 crFY26₹14.2FY26₹328 crFY260.01as of 30 Sep 202612 Nov 2026
Max Healthcare (MAXHEALTH)₹8,373 crFY26₹17.2FY26₹149 crFY260.27as of 31 Mar 202611 Nov 2026
Morepen Laboratories (MOREPENLAB)₹1,806 crFY26₹5.3FY26−₹128 crFY260.22as of 30 Sep 202612 Nov 2026
Natco Pharma (NATCOPHARM)₹4,078 crFY26₹34.8FY26₹1,377 crFY260.08as of 31 Mar 202616 Nov 2026
Piramal Pharma (PPLPHARMA)₹8,869 crFY26₹-3.7FY26₹763 crFY260.69as of 30 Sep 202612 Nov 2026
Sun Pharma (SUNPHARMA)₹58,462 crFY26₹19.6FY26₹8,810 crFY260.03as of 30 Sep 202611 Nov 2026
Torrent Pharma (TORNTPHARM)₹13,980 crFY26₹15.5FY26₹2,346 crFY260.76as of 30 Sep 202612 Nov 2026
Zydus Lifesciences (ZYDUSLIFE)₹27,148 crFY26₹18.8FY26−₹555 crFY260.48as of 30 Sep 202617 Nov 2026

Net profit per ₹100 of revenue: Cityfort calculation from each company's annual numbers (net profit ÷ revenue × 100). Banks and NBFCs report total income (interest earned plus other income) as revenue, and free cash flow and debt-to-equity are not used for lenders. Free cash flow: cash from operations minus capital spending, as on each company's page. Debt-to-equity: borrowings ÷ net worth, as on each company's page for the balance-sheet date shown. Sources for every figure are on each company's page. ₹ crore, as each company reports.

How companies in this sector earn

How do Healthcare companies make money?

  • Drug makers sell branded medicines through doctors' prescriptions in India, and cheaper generic copies abroad, mainly in the United States.
  • Some firms make the active ingredients (APIs) that go into medicines, or make drugs under contract for other companies.
  • Research, raw materials and the cost of meeting quality rules are the biggest costs for drug makers.
  • Hospitals earn from each patient's bed stay, surgery and tests, so how full the beds are matters.
  • Diagnostic labs earn a fee per test and depend on how many tests their collection centres bring in.

Who regulates it

Central Drugs Standard Control Organisation (CDSCO) · National Pharmaceutical Pricing Authority (NPPA) · Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers · US Food and Drug Administration (USFDA), for exports to the United States

What moves results across the sector

  • US generic drug prices and USFDA inspection results at Indian plants.
  • Price controls on essential medicines set by the NPPA.
  • Prices of key ingredients imported from China, and the rupee-dollar exchange rate.

Words you'll meet

Key terms

Generic drug
A copy of a medicine whose patent has expired, sold at a lower price than the original.
API (active pharmaceutical ingredient)
The chemical in a medicine that produces its effect.
USFDA observation
A problem noted by the US drug regulator after inspecting a plant; serious findings can stop sales to the US.
ANDA
The application a company files to sell a generic drug in the United States.
ARPOB
Average revenue per occupied bed per day, a key figure for hospitals.
Occupancy
The share of a hospital's beds that are filled with patients.

Key facts

Healthcare in numbers

How big is India's pharmaceutical industry?
India's pharmaceutical turnover was ₹471,898 crore in FY25 (2024-25), per the Department of Pharmaceuticals. The department says the industry is the world's third largest by volume and eleventh largest by value. (Source: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India)
How much medicine does India export and import?
In FY25 (2024-25), India exported pharmaceuticals worth ₹245,962 crore and imported pharmaceuticals worth ₹63,573 crore, per the Department of Pharmaceuticals, citing DGCIS. (Source: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India)

Sources

  1. Annual Report 2025-26, Chapter 1: Overview, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India, 2 Mar 2026

Last updated 25 Oct 2026.

Disclaimer

For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.

Read the full disclaimer

Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.

All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management are reported as statements, with their date and source; they are not our forecasts.